CUAMC
BOLT icon

China Universal Asset Management Company’s Bolt Biotherapeutics BOLT Stock Holding History

China Universal Asset Management Company’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18
Closed -$1K – 403
2022
Q3 		$1K Buy
+18
New +$745 ﹤0.01% 384

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

China Universal Asset Management Company's BOLT Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Bolt Biotherapeutics (BOLT) in Q4 2022, closing a stake of 18 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in BOLT in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 44 funds tracked by Wall St. Rank hold BOLT as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Bolt Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 18 Bolt Biotherapeutics shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Bolt Biotherapeutics in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Bolt Biotherapeutics position peaked at $1K in Q3 2022.
  • 44 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.